Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 9/20 | 0.78 |
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 5/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7915394 | 0.89 | HINT1 (0.71) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5219707 | 0.88 | GSK3A (0.80) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295421 | 0.87 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295418 | 0.87 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL2994004 | 0.87 | HINT1 (0.72) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL1533274 | 0.87 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL784432 | 0.85 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5358571 | 0.85 | HINT1 (0.70) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL6065959 | 0.85 | HINT1 (0.77) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL8506523 | 0.85 | POLB (0.61) | HINT1GSK3ARPS6KA3MAPK14PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250171783-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-12-19 | — | — | US | disclosed |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | SAREPTA THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230407301-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5698685-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5506337-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | COL2A1, COL14A1, UPF1 | HINT1 4239/4885GSK3A 3705/4885RPS6KA3 2603/4885 |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | GAA, GBA3, GBA1 | HINT1 1688/4885GSK3A 2533/4885RPS6KA3 3371/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | HINT1 2114/4885GSK3A 3484/4885RPS6KA3 1845/4885 |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | HINT1 3092/4885GSK3A 2592/4885RPS6KA3 2789/4885 |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | DCLRE1B, OGG1, DCTD | HINT1 3067/4885GSK3A 2439/4885RPS6KA3 4196/4885 |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | HINT1 1688/4885GSK3A 2533/4885RPS6KA3 3371/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | HINT1 4354/4885GSK3A 3965/4885RPS6KA3 2703/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | HINT1 3092/4885GSK3A 2592/4885RPS6KA3 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.